<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xml:lang="KO" article-type="research-article">
<front>

<journal-meta>
<journal-id journal-id-type="nlm-ta">J Korean Orthop Assoc</journal-id>
<journal-id journal-id-type="publisher-id">JKOA</journal-id>
<journal-title-group>
<journal-title>Journal of the Korean Orthopaedic Association</journal-title>
</journal-title-group>
<issn pub-type="ppub">1226-2102</issn>
<issn pub-type="epub">2005-8918</issn>
<publisher>
<publisher-name>The Korean Orthopaedic Association</publisher-name>
</publisher>
</journal-meta>

<article-meta>
<article-id pub-id-type="doi">10.4055/jkoa.2003.38.5.519</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Clinical Significance of VEGF and TGF-beta Expression in Osteosarcoma</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jung</surname>
<given-names>Sung Taek</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Moon</surname>
<given-names>Eun Sun</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Yong Uk</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Seung Sik</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Gye Jin</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Yang Kyung</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
</contrib-group>

<aff id="A1">Department of Orthopedic Surgery, Chonnam National University Hospital, Gwangju, Korea.</aff>

<author-notes>
<corresp>
<email>stjung@chonnam.ac.kr</email>
</corresp>
</author-notes>

<pub-date pub-type="ppub">
<month>09</month>
<year>2003</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>01</month>
<year>2018</year>
</pub-date>
<volume>38</volume>
<issue>5</issue>
<fpage>519</fpage>
<lpage>525</lpage>

<permissions>
<copyright-statement>Copyright &#x00A9; 2003 The Korean Orthopaedic Association</copyright-statement>
<copyright-year>2003</copyright-year>
</permissions>

<abstract>
<sec>
<title>Introduction</title>
  <p>The transforming growth factor-beta (TGF-beta ) is a multipotent glycoprotein that has been implicated in tumor development. The vascular endothelial growth factor (VEGF), which is an endothelial-specific mitogen that is overexpressed in various malignancies, is believed to be a potent regulator of angiogenesis. Osteosarcoma was examined to determine firstly, if VEGF and the TGF-beta isoform were overexpressed in this sarcoma, and secondly, if the degree of expression might represent a significant biologic predictor for disease-specific survival.</p>
</sec>
<sec>
<title>Materials and Methods</title>
  <p>Selected paraffin-embedded tissues of surgical specimens from 25 patients of prechemotherapy case with osteosarcoma, who were treated between 1995 and 2001 were stained with rabbit polyclonal anti-VEGF and TGF-beta isoform antibodies.</p>
</sec>
<sec>
<title>Results</title>
  <p>The majority of high-grade osteosarcomas in this study had a high intensity TGF-beta 2, - 3 and VEGF expression levels. The three in 5 patients who died of the disease had a high VEGF expression level. However VEGF expression was only independent predictor of overall survival.</p>
</sec>
<sec>
<title>Conclusion</title>
  <p>Further studies about TGF-beta and VEGF may provide useful information for understanding of pathophysiology of osteosarcoma.</p>
</sec>
</abstract>

<kwd-group>
<kwd>Osteosarcoma</kwd>
<kwd>Transforming growth factor-beta (TGF-beta)</kwd>
<kwd>Vascular endothelial growth factor (VEGF)</kwd>
<kwd>Immunohistochemistry</kwd>
</kwd-group>
</article-meta>
</front>
</article>
